G1 Therapeutics (GTHX) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow

• Categorized by lack of HR expression and HER2 gene amplification - Trilaciclib demonstrated robust survival benefit with chemo in Ph2 Chemo +/- targeted therapy remains first-line TNBC SoC - ~9k annual first-line drug treated TNBC patients in the U.S. - Targeted therapies only demonstrated benefit in subpopulations Trilaciclib demonstrated broad benefit in Randomized Phase 2 - Benefit observed across PD-(L)1+ and PD-(L)1- subpopulations - Patients receive 4 vials of trilaciclib for each 3-week cycle Poten ...